头孢硫脒与6种抗菌药物联用对金葡球菌的体外抗菌活性

目的:评价头孢硫脒分别与万古霉素、奈替米星、阿米卡星、环丙沙星、左氧氟沙星和加替沙星6种抗菌药物联合用药,对于临床分离的金葡球菌(SA)的体外联合抗菌效应.方法:经VITEK鉴定临床分离致病菌,采用棋盘法设计,微量肉汤稀释法测定6组抗菌药物对SA及耐甲氧西林金葡球菌(MRSA)的最低抑菌浓度,并计算部分抑菌指数(FIC指数). 结果:头孢硫脒与万古霉素、奈替米星、阿米卡星、环丙沙星、左氧氟沙星、加替沙星联合应用后,MIC50,MIC90明显降低,FIC指数<0.5占60%～90%,0.5～1占10%～30%,1～2占0～13.3%,>2为0.结论:头孢硫脒与6种抗菌药物联合应用后,对SA基本表现为协同和相加作用,说明联合用药的疗效要高于两药单独使用.     

头孢硫脒与奈替米星对90株革兰阳性球菌联合药敏研究

目的评价头孢硫脒与奈替米星对90株G+球菌体外联合抗菌效应.方法采用棋盘法设计,微量肉汤稀释法测定.测定不同浓度组合的三组抗菌药物对90株临床分离的G+球菌的最低抑菌浓度,并计算FIC指数.结果头孢硫脒对金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌的MIC50分别为16mg/L、1mg/L、2mg/L,与奈替米星联合应用后,其MIC50分别显著的降低至0.5mg/L、0.125mg/L、0.25mg/L.FIC指数结果表明头孢硫脒与奈替米星抗菌药物联合应用,对金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌多数呈协同和相加作用,并以协同作用为主(66.7%～90%),无关作用较少(0～6.6%),无拮抗作用.结论头孢硫脒与奈替米星联合应用对90株G+球菌呈基本协同或相加作用.     

头孢硫脒与奈替米星对90株革兰阳性球菌联合药敏研究

目的:评价头孢硫脒与奈替米星对90株G+球菌体外联合抗菌效应.方法:采用棋盘法设计,微量肉汤稀释法测定.测定不同浓度组合的三组抗菌药物对90株临床分离的G+球菌的最低抑菌浓度,并计算FIC指数.结果:头孢硫脒对金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌的MIC50分别为16mg/L、1mg/L、2mg/L,与奈替米星联合应用后,其MIC50分别显著的降低至0.5mg/L、0.125mg/L、0.25mg/L.FIC指数结果表明头孢硫脒与奈替米星抗菌药物联合应用,对金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌多数呈协同和相加作用,并以协同作用为主(66.7%～90%),无关作用较少(0～6.6%),无拮抗作用.结论:头孢硫脒与奈替米星联合应用对90株G+球菌呈基本协同或相加作用.     

利奈唑胺、替考拉宁和万古霉素等抗菌药物对常见需氧革兰阳性球菌的体外抗菌活性

目的评价利奈唑胺、替考拉宁和万古霉素等抗菌药物的体外抗菌活性。方法采用琼脂稀释法对临床收集的132株革兰阳性球菌进行抗菌活性测定,记录其各自的MIC并进行比较。结果利奈唑胺、替考拉宁及万古霉素3药对革兰阳性球菌均有较大抗菌活性,敏感率均为100%,包括其中的耐甲氧西林葡萄球菌和青霉素中介肺炎链球菌均有良好抗菌作用。3药在部分革兰阳性球菌的抗菌作用中与利福平相仿,但比氨基糖苷类抗生素和氟喹诺酮类抗菌药强。在对甲氧西林敏感金葡萄的抗菌活性中,替考拉宁的MIC90均为利奈唑胺和万古霉素的4倍;在对甲氧西林敏感凝固酶阴性葡萄球菌的抗菌活性中,替考拉宁的MIC90分别均为利奈唑胺和万古霉素的8倍;而在青霉素敏感和中介肺炎链球菌的抗菌活性中,替考拉宁的MIC90为利奈唑胺的1/16,为万古霉素的1/8;在肠球菌属的抗菌活性中,万古霉素的MIC90分别为利奈唑胺的2倍,是替考拉宁的4倍和8倍。结论利奈唑胺、替考拉宁以及万古霉素等三药对革兰阳性球菌有较大的抗菌作用,对部分革兰阳性菌的抗菌作用与利福平相仿,但比其他如氨基糖苷类抗生素和氟诺酮类抗菌药更优,是临床革兰阳性球菌严重感染的有效药物。     

耐甲氧西林金葡菌的头孢西丁检测法与耐药性分析

目的评价头孢西丁纸片扩散法检测耐甲氧西林金葡菌（MRSA）的效果．了解MRSA的耐药状况。方法用头孢西丁及苯唑西林纸片扩散法、mecA基因聚合酶链反应（PCR）检测MRSA．并以mecA基因PCR法为参考方法与头孢西丁及苯唑西林纸片扩散法检测MRSA进行比较分析。按CLSI（原NCCLS）规定的标准测定MRSA对青霉素等10种抗生素的耐药率（KB法）。结果95株金葡菌（SA）中mecA基因阳性株42株。头孢西丁纸片法筛选出40株MRSA，其中39株mecA基因阳性，方法特异性为97．5％，灵敏度92．9％；苯唑西林纸片法筛选出44株MRSA，其中36株mecA基因阳性．方法特异性为81．8％．灵敏度85．7％。MRSA对青霉素、苯唑西林100％耐药，对万古霉素全部敏感．对红霉素、头孢唑林、克林霉素、氨苄西林／舒巴坦、头孢呋辛、左氧氟沙星、奈替米星呈不同程度耐药。结论头孢西丁纸片扩散法检测MRSA特异性和灵敏度优于苯唑西林纸片扩散法。MRSA具有多重耐药性．须加强其对抗生素的耐药性监测。     

国产替考拉宁体内外抗菌作用研究

目的：为了评价国产替考拉宁对510株临分离菌的体外抗菌活性，并与进口产品替考拉宁及万古霉素进行比较，方法：采用琼脂二倍稀释法和试管二倍稀释法测定药物的最低抑菌浓度（MIC）及最低杀菌浓度（MBC）。结果：国产替考拉宁的抗菌活性与万古霉素相似或略强，其对MRSDA和MSSA的MIC50分别为4、1mg/L，对MRSE和MSSE的MIC50分别为1、0.5mg/L。对所试大多数菌株MIC50为0．06－4mg/L，与进口的替考拉宁的抗菌活性无显著差异，替考拉宁在2－4MIC浓度时呈杀菌作用，替考拉宁的MIC值随接种菌量增加升高2－8倍，受PH和血清浓度影响不大，体内保护试验表明，替考拉宁静脉和皮下给药对金葡球菌981925、肺炎链球菌98135和肠球菌9804所致小鼠全身感染的ED50分别为0．59、0．38、0．17mg/kg（静脉注射）和1．08、0．87、0．36mg/kg（皮下注射）。其体内抗菌作用比万古霉素中6－12倍以上。     

亚胺培南／西司他丁联合奈替米星对甲氧西林耐药金葡球菌感染小鼠败血症体内协同抗菌作用研究

目的评价亚胺培南/西司他丁联合奈替米星对甲氧西林耐药金黄色葡萄球菌感染小鼠模型的体内保护作用。方法0.5ml1MLD菌量甲氧西林耐药金黄色葡萄球菌感染小鼠,然后皮下给0.2ml的亚胺培南/西司他丁联合奈替米星药液。结果亚胺培南/西司他丁联合奈替米星对MRSA98-15、MRSA98-17感染小鼠的半数有效量ED50值分别为16.39和10.62mg     

头孢硫脒与其他6种抗菌药物对表皮葡萄球菌体外联合药敏的研究

目的 :评价头孢硫脒分别与万古霉素、奈替米星、阿米卡星、环丙沙星、左氧沙星和加替沙星等 6种抗菌药物联合用药 ,对于表皮葡萄球菌 (Staphylo coccusepidermidis ,SE)的体外联合抗菌效应。方法 :采用棋盘法设计 ,微量肉汤稀释法测定不同浓度组合的 6组抗菌药物对 30株临床分离的表皮葡萄球菌的最低抑菌浓度 (MIC) ,并计算部分抑菌指数 (FIC指数 )。结果 :头孢硫脒对表皮葡萄球菌的MIC50 、MIC90 为 1、6 4mg·L-1;与万古霉素、奈替米星、阿米卡星、环丙沙星、左氧沙星、加替沙星联合应用后 ,其MIC50 分别降低至 0 .12 5、0 .12 5、0 .12 5、0 .12 5、0 .2 5、0 .12 5mg·L-1,MIC90 分别降低至 1、1、1、2、1、1mg·L-1。结论 :6种抗菌药物与头孢硫脒联合用药后 ,对表皮葡萄球菌球菌基本表现为协同或相加作用 ,并以协同作用为主 ,无关作用较少 ,无拮抗作用。     

注射用法罗培南钠对金葡菌的体内外抗菌活性研究

目的研究注射用法罗培南钠对临床分离的金葡菌的体内外抗菌活性。方法用头孢西丁纸片法在近年来本室保存的临床分离金葡菌中筛选耐甲氧西林的金葡菌（methicillin resistant staphylococcus aureus，MRSA），用琼脂平板稀释法测定法罗培南和万古霉素对甲氧西林敏感的金葡菌（methicillin sensitive staphylococcus aureus，MSSA）和MRSA菌株的最低抑菌浓度（minimal inhibitory concentration．MIC）。根据MIC选择对法罗培南敏感、中度和高度耐药的MRSA菌株及1株MSSA建立小鼠腹膜炎模型，以注射用法罗培南钠及万古霉素通过静脉注射进行感染动物的治疗，评价对感染小鼠的保护作用。结果151株金葡菌中共分离出65株MRSA．阳性率为43％；体外试验法罗培南和万古霉素对86株MSSA均敏感。65株MRSA对法罗培南敏感者10株，其余均耐药；对万古霉素均敏感。注射用法罗培南钠对4株菌的ED50分别为38．3、38．6、71．9和7．07mg／kg；万古霉素则为2．25、10．18、20．85和1．77mg／kg。结论注射用法罗培南钠对MSSA有良好的体内和体外抗菌活性；注射用法罗培南钠对MRSA无效．即使体外敏感。     

头孢硫脒等6种抗菌药物对革兰氏阳性球菌体外抗菌活性研究

目的 对比研究头孢硫脒(CTM)、头孢唑林(CEZ)、头孢映辛(CXM)、头孢曲松(CRO)、苯唑西林(MPIPC)、万古霉素(VCM)对99株临床分离革兰氏阳性球菌的抗菌活性。方法采用琼脂平板稀释法测定最低抑菌浓度(MIC)。结果 CTM对32株金黄色葡萄球菌的MIC50、MIC90均为0．5mg/L，低于CRO，CTM对29株表皮葡萄球菌的MIC50、MIC90分别为0．125和8mg/L，是CRO的l／16，对9株甲氧西林耐药的葡萄球菌(MRS)的范围与CXM相近；CTM对粪肠球菌的抗菌活性与万古霉家相仿，强于CEZ、CXM、CRO、LGIPC。结论头孢硫腺对葡萄球菌和粪肠球菌具有很强的体外抗菌活性。     

Comparative in vitro activity of nine antistaphylococcal agents against 275 recent isolates of Gram-positive cocci

The aim of this study was to compare the in vitro activities of 9 antistaphylococcal agents including teicoplanin (TEI) against 275 non-repetitive clinical strains representing 15 species of staphylococci and 27 strains of Enterococcus (E.) faecalis, isolated from various specimens between 1991-1992 at a Canadian teaching hospital. The NCCLS agar dilution method was used (10(4) colonyforming units/spot). In terms of MIC(90), TEI and vancomycin (VAN) appeared to be the most potent antibiotics against all staphylococci tested (TEI: 2.0-4.0 mug/ml; VAN: 1.0-2.0 mug/ml; ciprofloxacin (CPF): 0.25-32 mug/ml; cefazolin (CEF): 8.0-256 mug/ml; methicillin (MET): 2.0->256 mug/ml; imipenem (IMP): 1.0-32 mug/ml; erythromycin (ERT): 16->256 mug/ml; ampicillin (AMP): 16-128 mug/ml; fusidic acid (FSA): 0.5-16 mug/ml). Multiple resistant strains, including MET-resistant Staphylococcus (Staph.) aureus and Staph. epidermidis, were susceptible to TEI and VAN with respective MICs of 2-4 mug/ml and 1-2 mug/ml regardless of specimen type. Moreover, TEI was highly active against E. faecalis (MIC(90) for TEI and VAN: 0.5 and 4.0 mug/ml, respectively).     

Discrepancies between mecA PCR and conventional tests used for detection of methicillin resistant Staphylococcus aureus

Conventional and molecular techniques are being used in the detection of methicillin resistance in Staphylococcus aureus but they do not always show concordant results. In this study, a mecA PCR-based amplification was compared with the 1 microg oxacillin disk diffusion test and the Epsilometer test (E-test) for detection of MICs. Among 31 isolates initially characterized as MRSA by the disk diffusion test, mecA was detected in only 13 (42%) isolates. The E-test showed a wide range of oxacillin MICs (0.5 - > 256 microg/ml) among these 31 MRSA isolates: seven isolates had an MIC of > 256 microg/ml, one had 64 microg/ml, two had 4 microg/ml, two had 3 microg/ml, one had 2.5 microg/ml, nine had 2 microg/ml, three had 1.5 microg/ml, five had 1 microg/ml and one had 0.5 microg/ml. Comparing the mecA PCR results with the E-test oxacillin MIC findings revealed that mecA was detected in seven of eight isolates (87.5%) with an MIC of > or = 64 microg/ml, in three of 14 isolates (21.4%) with an MIC of 2-4 microg/ml and in three of nine isolates (33.3%) with an MIC of < 2 microg/ml. Beta-lactamase production was positive in 28/31 isolates (90.3%). Because of this variation between tests and since several resistance mechanisms are known to mediate methicillin resistance in S. aureus, the reliable detection of MRSA cannot be solely based on detection of mecA gene in S. aureus. At this stage and until new guidelines are introduced by an official body, such as NCCLS, a combination of conventional methods alone or together with a molecular method should be used every time S. aureus is tested for detection of methicillin resistance.     

国产米诺环素对耐甲氧西林金葡球菌的体外抗菌活性观察

用琼脂稀释法进行国产米诺环素对１０４株耐甲氧西林金葡球菌（ＭＲＳＡ）和１２０株甲氧西林敏感金葡球菌（ＭＳＳＡ）的抗菌活性研究，并与日本产米诺环素等进行了抗菌作用比较。结果表明国产米诺环素对ＭＲＳＡ和ＭＳＳＡ的抑菌效果，与日本产米诺环素基本一致。对ＭＲＳＡ的ＭＩＣ５０和ＭＩＣ９０前者分别为２和８ｍｇ／Ｌ，而后者分别为２和４ｍｇ／Ｌ。两者对ＭＳＳＡ的ＭＩＣ５０和ＭＩＣ９０均为０．５和４ｍｇ／Ｌ。国产米诺环素与其它６种抗生素比较，除去甲万古霉素外，其对ＭＲＳＡ和ＭＳＳＡ的抗菌效果，均优于头孢唑林等抗生素     

Methicillin- and gentamicin-resistant Staphylococcus aureus: susceptibility to fosfomycin, cefamandole, N-formimidoyl-thienamycin, clindamycin, fusidic acid and vancomycin

The in vitro activity of fosfomycin against 90 strains of methicillin- and gentamicin-resistant Staphylococcus aureus was studied in an in vitro microtitre system using Mueller-Hinton broth supplemented with glucose-6-phosphate. In parallel the antistaphylococcal activity of cefamandole, N-formimidoyl-thienamycin, clindamycin, fusidic acid and vancomycin was determined with the same organisms. The following MIC50 (MIC95) values were obtained: fosfomycin 8 (128) mg/l, cefamandole 8 (greater than 64) mg/l, clindamycin 0.25 (16) mg/l, fusidic acid less than 0.25 (less than 0.25) mg/l, vancomycin 1 (2) mg/l and N-formimidoyl-thienamycin 4 (16) mg/l. A high MIC/MBC ratio was noted for cefamandole, in contrast to fosfomycin.     

Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)

Medical centres in eight countries in the Asia-Pacific region provided 2391 isolates for the SENTRY Antimicrobial Surveillance Program during 2003-2004 to determine their susceptibility to several antimicrobial classes, including daptomycin. Daptomycin, vancomycin and teicoplanin minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined for 120 isolates of Staphylococcus aureus, which included wild-type (WT) methicillin-resistant S. aureus (MRSA) and strains with decreased susceptibility to vancomycin (hetero-vancomycin-intermediate S. aureus (hVISA)). Oxacillin-resistant staphylococcal isolates were much less susceptible to the other tested agents compared with oxacillin-susceptible strains. Vancomycin resistance was higher among Enterococcus faecium (10.3%) than Enterococcus faecalis (0.4%), and macrolide resistance was high both for beta-haemolytic (17.7%) and viridans group (48.7%) streptococci. Daptomycin (MIC for 90% of the organisms (MIC(90))=0.5-1mg/L) was two-fold more potent than vancomycin, with >99% susceptibility when tested against staphylococci. All tested isolates of E. faecalis (MIC(90)=2mg/L) and beta-haemolytic streptococci (MIC(90)=0.5mg/L) were susceptible to daptomycin. Daptomycin MIC and MBC values were slightly higher for the hVISA isolates compared with WT-MRSA, with MBC/MIC ratios of only 1-2 for both groups. The MBC/MIC ratio for vancomycin was often greater when tested against these strains, particularly hVISA. In contrast, teicoplanin MBC/MIC ratios were significantly higher, with many of the strains showing values consistent with tolerance (>or=32). Daptomycin was demonstrated to have excellent in vitro activity when tested against Gram-positive isolates collected from Asia-Pacific countries, including hVISA strains.     

Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study

Resistance rates amongst Gram-negative pathogens are increasing in the Asia-Pacific region. The Comparative Activity of Carbapenem Testing (COMPACT) II study surveyed the carbapenem susceptibility and minimum inhibitory concentrations (MICs) of doripenem, imipenem and meropenem against 1260 major Gram-negative pathogens isolated from hospitalised patients at 20 centres in five Asia-Pacific countries (New Zealand, the Philippines, Singapore, Thailand and Vietnam) during 2010. Pseudomonas aeruginosa (n=625), Enterobacteriaceae (n=500), and other Gram-negative pathogens including Acinetobacter baumannii (n=135) were collected from patients with bloodstream infection (32.2%), nosocomial pneumonia including ventilator-associated pneumonia (58.1%), and complicated intra-abdominal infection (9.7%), with 36.7% being isolated from patients in an Intensive Care Unit. As high as 29.8% of P. aeruginosa and 73.0% of A. baumannii isolates were not susceptible to at least a carbapenem, whereas the majority of Enterobacteriaceae (97.2%) were susceptible to all carbapenems. Respective MIC(50)/MIC(90) values (MICs for 50% and 90% of the organisms, respectively) of doripenem, imipenem and meropenem were: 0.38/8, 1.5/32 and 0.38/16 mg/L for P. aeruginosa; 0.023/0.094, 0.25/0.5 and 0.032/0.094 mg/L for Enterobacteriaceae; and 32/64, 32/128 and 32/64 mg/L for A. baumannii. Doripenem and meropenem had comparable activity against P. aeruginosa, both being more active than imipenem. All carbapenems were highly potent against Enterobacteriaceae, although imipenem demonstrated higher MIC values than doripenem and meropenem. The three carbapenems showed less activity against A. baumannii. The high prevalence of carbapenem resistance amongst important nosocomial pathogens (P. aeruginosa and A. baumannii) warrants rigorous infection control measures and appropriate antimicrobial use in the Asia-Pacific region.     

In vitro antimicrobial susceptibilities of 349 methicillin-resistant Staphylococcus aureus isolates from veterans

Three hundred and forty-nine methicillin resistant Staphylococcus aureus (MRSA) isolates from veterans were tested (by disc agar diffusion) for their in vitro activity against 18 antimicrobial agents. At least 90% of the isolates were susceptible to bacitracin, nitrofurantoin, hydrogen peroxide, novobiocin, netilmicin and vancomycin. We feel that the aminoglycoside, netilmicin, might provide an alternative agent (to intravenously administered vancomycin) for treating multiply-antimicrobial resistant MRSA. In addition, hydrogen peroxide exhibited very good activity against the test isolates and may have some use as a topical agent for reduction of MRSA on skin and some mucous membranes. This study suggests that further evaluation of netilmicin and hydrogen peroxide (topical only) might be useful.     

Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002

Antibacterial activities of gatifloxacin (GFLX) and other antibacterial drugs against various fresh clinical strains (800 isolates) isolated from specimens of patients in 2002 were compared. GFLX was more active than levofloxacin and ciprofloxacin against Gram-positive bacteria such as methicillin susceptible Staphylococcus aureus and Streptococcus pneumoniae. For these isolates, clarithromycin and azithromycin were less active (MIC90; > 16- > 64 micrograms/mL), GFLX was more active than cefdinir. For Escherichia coli, Klebsiella pneumoniae, Acinetobacter species, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis, three quinolones including GFLX were potently active (MIC90; < or = 0.06-0.5 microgram/mL). Pseudomonas aeruginosa isolated from urinary tract infections were resistant to three quinolones including GFLX (MIC90; 32-64 micrograms/mL), however P. aeruginosa isolated from respiratory and otolaryngological infections were more susceptible (MIC90; 0.5-2 micrograms/mL). Quinolones were less active against Neisseria gonorrhoeae as compared with the cephem antibiotics tested, but GFLX was the most active against N. gonorrhoeae among the quinolones tested. In this study, we investigated activity of GFLX against fresh clinical strains isolated early in 2002, GFLX is widely and potently active against S. aureus, S. pneumoniae and various Gram-negative bacteria.     

山楂果胶寡糖联用氟喹诺酮类药物对葡萄球菌防耐药浓度的影响分析

目的探讨山楂果胶寡糖与氟喹诺酮联合用药对金黄色葡萄球菌防耐药浓度的影响,为临床合理使用现有抗生素、防治细菌耐药产生提供理论依据。方法采用标准琼脂二倍稀释法测定左氧氟沙星、环丙沙星对30株临床分离的金黄色葡萄球菌和金黄色葡萄球菌质控菌株ATCC25923的最低抑菌浓度（MIC）,采用标准琼脂平板稀释法测定2种FQ药物对临床分离金黄色葡萄球菌的防突变浓度,计算单药和联合山楂果胶寡糖用药后该药的MPC50、MPC90。结果左氧氟沙星单药对30株金黄色葡萄球菌的MPC范同在2～64mg／L,MPC90为32mg／L;联合山楂果胶寡糖后MPC范围为0．5～16mg／L,MPC90降至8mg／L。环丙沙星单药对30株金黄色葡萄球菌的MPC范围1～32mg／L,MPC90为16mg／L;联合山楂果胶寡糖后MPC范围0．25～8mg／L,MPC90降至4mg／L,两组各项指标比较差异有显著性伊〈0．05）。结论联合山楂果胶寡糖用药能降低环丙沙星、左氧氟沙星MPC,减少细菌耐药突变体的选择性富集扩增,防止抗菌药物耐药的产生。     

山楂果胶寡糖联用氟喹诺酮类药物对葡萄球菌防耐药浓度的影响分析

目的 探讨山楂果胶寡糖与氟喹诺酮联合用药对金黄色葡萄球菌防耐药浓度的影响,为临床合理使用现有抗生素、防治细菌耐药产生提供理论依据.方法 采用标准琼脂二倍稀释法测定左氧氟沙星、环丙沙星对30株临床分离的金黄色葡萄球菌和金黄色葡萄球菌质控菌株ATCC25923的最低抑菌浓度(MIC),采用标准琼脂平板稀释法测定2种FQ药物对临床分离金黄色葡萄球菌的防突变浓度,计算单药和联合山楂果胶寡糖用药后该药的MPC50、MPC90.结果 左氧氟沙星单药对30株金黄色葡萄球菌的MPC范围在2～64mg/L,MPC90为32mg/L;联合山楂果胶寡糖后MPC范围为0.5～16 mg/L,MPC90降至8 mg/L.环丙沙星单药对30株金黄色葡萄球菌的MPC范围1～32mg/L,MPC90为16mg/L;联合山楂果胶寡糖后MPC范围0.25～8mg/L,MPC90降至4 mg/L,两组各项指标比较差异有显著性(P<0.05).结论 联合山楂果胶寡糖用药能降低环丙沙星、左氧氟沙星MPC,减少细菌耐药突变体的选择性富集扩增,防止抗菌药物耐药的产生.